- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Richard Willke on Using Real-World Data to Inform Value-Based Contracts
There is a trend of making value-based deals to pay for treatments in order to ensure the drug works as advertised while also protecting payers from financial risk, explained Richard J. Willke, PhD, chief science officer of ISPOR.
There is a trend of making value-based deals to pay for treatments in order to ensure the drug works as advertised while also protecting payers from financial risk, explained Richard J. Willke, PhD, chief science officer of ISPOR.
Transcript
What is the importance of real-world data as more payers look to make value-based deals with pharma companies (such as the contracts Harvard Pilgrim signed with Eli Lilly for Forteo and Amgen for Enbrel)?
All I know about these agreements is what I’ve seen in the media, but they are part of a trend towards using real-world data to supply more information for these performance-based risk-sharing agreements. They generally base these agreements and the payments for these agreements on outcomes of treatment—and I think that’s the basis for the Enbrel deal—but they can be on another measure, like adherence, which as I understand is the basis for the Forteo deal.
Usually the underlying rationale is that the producer gets full payment if the treatment performs as advertised or as labeled. And if it doesn’t, then the payer is protected from some of the financial risk of the deal. The only way you know how it’s performing is to collect data on the outcomes, so most of these deals are accompanied by a careful data collection plan.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
